
Billiontoone Inc (BLLN) Stock Forecast & Price Target
Billiontoone Inc (BLLN) Analyst Ratings
Bulls say
BillionToOne is a promising stock due to its unique and innovative QCT platform for prenatal and cancer testing, strong market position in NIPT and oncology, and strong financials with consistent profitability and a strong operating margin. The recent decline in share price presents a buying opportunity, and the company's focus on innovation and new product launches suggest future growth potential.
Bears say
BillionToOne is facing potential challenges in the short-term due to a decline in true-ups and pending payment from a large payer, but the team has confirmed that the demand for their ultrasensitive tests remains strong and expect to see continued growth in their prenatal testing segment. However, concerns about management turnover and possible competition in their pipeline markets could provide longer-term risks. Despite their promising technology platform and impressive financials, tension in valuation within the specialty lab peer group has led us to decrease our price target from $142 to $130.
This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.
Billiontoone Inc (BLLN) Analyst Forecast & Price Prediction
Start investing in Billiontoone Inc (BLLN)
Order type
Buy in
Order amount
Est. shares
0 shares